The CIR’s experience with live attenuated recombinant chimeric vaccine candidates against dengue virus is extensive and includes the following vaccines:
- rDEN2/4?30 (ME)
- rDEN1?30 (ME)
- rDEN4?30-200, 201
- rDEN3/4?30 (ME)
Future trials at the CIR will evaluate the rDEN4?30-7163 vaccine candidate as well as new heterologous and tetravalent candidates.
Here is a link to a list of selected publications by CIR faculty about Dengue virus.
The CIR has conducted a trial using the live attenuated recombinant chimeric vaccine candidate WN/DEN4?30, delivered in a single dose, with plans to evaluate the efficacy of a booster dose.